Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 3, 2006, Pages 1173-1177

  Lewandowski, K C ^a   Komorowski, J ^b   O'Callaghan, C J ^c   Tan, B K ^a   Chen, J ^a   Prelevic, G M ^d   Randeva, H S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c QUEEN S UNIVERSITY   (Canada)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ANOVULATION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL;

EID: 33644832165     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0648     Document Type: Article

References (38)

1. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H 2002 Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12:655-662
2. Galis ZS, Sukhova GK, Lark MV, Libby P 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503
3. Tayebjee MH, Lip GY, MacFadyen RJ 2005 Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance. Curr Med Chem 12:917-925
4. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Shultz R 2002 Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-1549
5. Shah PK 2000 Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Rev 8:31-39
6. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T 1998 Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32:368-372
7. Brew K, Dinakarpandian D, Nagase H 2000 Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283
8. Mun-Bryce S, Rosenberg GA 1998 Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163-1172
9. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP 2001 Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89:201-210
10. Planas AM, Sole S, Justicia C 2001 Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after focal cerebral ischemia. Neurobiol Dis 8:834-846
11. Montaner J, Alvarez-Sabin J, Molina CA, Angeles A, Abillera S, Arenillas J, Monasterio J 2001 Matrix metalloproteinase expression is related to haemorrhagic transformation after cardioembolic stroke. Stroke 32:2762-2767
12. Goldman S, Shalev E 2004 MMPs and TIMPs in ovarian physiology and pathophysiology. Front Biosci 9:2474-2483
13. Hulboy DL, Rudolph LA, Matrisian LM 1997 Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod 3:27-45
14. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 18:774-800
15. Conway GS, Agrawall R, Betteridge DJ, Jacobs HS 1992 Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 37:119-126
16. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z 2004 Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89:2160-2165
17. Rajkhowa M, Bichnell J, Jones M, Clayton RN 1994 Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 61:605-612
18. Wild RA, Painter RD, Coulson PB, Carruth KB, Ranney RB 1985 Lipoprotein lipid concentrations as cardiovascular risk in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946-950
19. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Matson LA, Crona N, Lundberg PA 1992 Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones. Fertil Steril 57:505-513
20. Zimmerman S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R, Krakoff LR 1992 Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 75:508-513
21. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586
22. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
23. Lahav-Baratz S, Kraiem Z, Shiloh H, Koifman M, Ishai D, Dirnfeld M 2003 Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. Fertil Steril 79:567-571
24. Shalev E, Goldman S, Ben-Shlomo I 2001 The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP-1) in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod 7:325-331
25. Gottsch ML, Van Kirk EA, Murdoch WJ 2002 Role of matrix metalloproteinase 2 in the ovulatory folliculo-luteal transition of ewes. Reproduction 124:347-352
26. Espey LL 1992 Ovulation as an inflammatory process. In: Sjoberg N, Hamberger L, Janson P, Owman C, Coelingh-Bennik H. eds. Local regulation of ovarian function. Park Ridge, NJ: Parthenon Publishing Group;183-200
27. Huet C, Monget P, Pisselet C, Monniaux D 1997 Changes in extracellular matrix components and steroidogenic enzymes during growth and atresia of antral ovarian follicles in the sheep. Biol Reprod 56:1025-1034
28. Espey LL 1994 Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 35:1299-1308
29. McIntush EW, Smith MF 1998 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in ovarian function. Rev Reprod 3:23-30
30. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K 2003 Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 42:201-206
31. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
32. Noji Y, Kaiinami K, Kawashiri M, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Tadegoshi T, Mabuchi H 2001 Circulation matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 39:380-384
33. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L 2003 Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579-1585
34. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM 2000 Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31:40-47
35. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C 1999 Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1:337-352
36. Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A 2004 The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696-3701
37. Laimer M, Kaser S, Kranebitter M, Sandhofer A, Muhlmann G, Schwelberger H, Weiss H, Patsch JR, Ebenbichler CF 2005 Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes Relat Metab Disord 29:498-501
38. Tayebjee MH, Lip GY, Blann AD, Macfadyen RJ 2005 Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115:205-210